BioDlink International Company Limited
東曜藥業股份有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1875)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference is made to the annual report of BioDlink International Company Limited (the "**Company**") for the year ended 31 December 2024 published on 28 April 2025 (the "**2024 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report. This announcement provides supplemental information to the 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide to the Shareholders and potential investors of the Company with the following additional information in relation to the Pre-IPO Share Option Scheme, the 2020 Restricted Share Award Scheme and the 2024 Restricted Share Award Scheme pursuant to the Rule 17.09 of the Listing Rules.

PRE-IPO SHARE OPTION SCHEME

Participants	The eligible participants under the Pre-IPO Share Option Scheme include employees and consultants (being former employees) of the Company and its subsidiaries.
Maximum number of Shares	The maximum number of Shares which may be issued upon the exercise of all Pre-IPO Share Options granted under the Pre-IPO Share Option Scheme (whether exercised, lapsed or outstanding) as authorized by the Board is 16,969,000 Shares, representing approximately 2.20% of the number of Shares in issue as at the date of the 2024 Annual Report.
Maximum entitlement of each participant	N/A

Exercise period	Subject to the terms of the Pre-IPO Share Option Scheme, the Pre-IPO Share Options granted and outstanding may be exercised within ten (10) years from the relevant date of grant.
Vesting schedule	The vesting schedule in respect of the Pre-IPO Share Options typically depends on the seniority of the grantee and/or the timing of the fulfillment of performance targets mainly relating to the research and development progress of certain drug candidates, and may be adjusted on a case-by-case basis with the Board's approval.
Exercise of option	Upon vesting of the Pre-IPO Share Options, an option holder may exercise the vested options by making an application to the Company in writing in accordance with the scheme rules, and pay the exercise price within a period specified by the Company.
Exercise price	The exercise price shall be the highest of the following three values as at the date of the Board's approval of the grant of the respective Pre-IPO Share Options: (i) the net asset value per Share based on the Company's most recent financial statements reviewed by its auditors; (ii) the price per Share in the Company's most recent capital injection; and (iii) US$1.00 per Share (which was the par value of each Share before the Companies Ordinance came into operation on March 3, 2014 and is taken as reference under the Pre-IPO Share Option Scheme), which is subject to adjustment in the event of subdivision, consolidation or reorganization of the Company's share capital. Subject to certain requirements, the exercise price shall be adjusted in accordance with a specified formula in the event of changes to the share capital of the Company. The exercise price shall also be adjusted upon any payment of cash dividends by the Company or any amalgamation of the Company with other companies. Prior to the listing of the Company's Shares on the Main Board of the Stock Exchange, the exercise price of all Pre-IPO Share Options were adjusted to approximately US$0.286 in accordance with the terms of the Pre-IPO Share Option Scheme.
Remaining life of the scheme	The prescribed period during which share options may be granted under the Pre-IPO Share Option Scheme has expired and no further grants may be made under the scheme as of the date of the 2024 Annual Report.

2020 RESTRICTED SHARE AWARD SCHEME

Maximum number of Shares	The aggregate number of Shares which may be allotted and issued to the trustees under the 2020 Restricted Share Award Scheme may not exceed 57,000,000 Shares, representing approximately 7.38% of the number of Shares in issue as at the date of the 2024 Annual Report.
Vesting schedule	The administration committee (the "**Administration Committee**") may determine the date on which a Restricted Award Share is to vest (the "**Vesting Date**"). Any Restricted Award Shares granted to a selected participant shall vest in such selected participant on the latest of (i) the Vesting Date in respect of such Restricted Award Shares; (ii) the date of the allotment and issue of such Restricted Award Shares by the Company to the relevant trustee; and (iii) the date of the receipt of the full amount of the grant consideration by the Company in respect of such Restricted Award Shares. If an offer by way of takeover, merger, scheme of arrangement, share repurchase or otherwise is made to all the holders of Shares (or all such holders other than the offeror, any person controlled by the offeror and any person acting in association or concert with the offeror) resulting in a change in control (as defined in the Takeovers Code) of the Company, and such offer becomes or is declared unconditional (i.e. all conditions to which such transaction is subject have been satisfied) prior to the vesting of Restricted Award Shares in the selected participant, then such Restricted Award Shares shall immediately so vest.
Acceptance of grant	After the Administration Committee has determined a selected participant and the terms and conditions of a grant, it shall notify the relevant trustee and the selected participant about these terms and conditions in writing. Upon receipt of such notification, the grant shall be deemed to be irrevocably accepted by the selected participant unless the selected participant notifies the Administration Committee in writing within five (5) business days that he/she declines to accept the grant.

Grant consideration	In determining the grant consideration of a grant under the 2020 Restricted Share Award Scheme, the Administration Committee shall take into consideration any matter it considers relevant. The grant consideration is to be paid by a selected participant to the Company as a condition to the vesting of his/her Restricted Award Shares on or after the relevant vesting date, but not when the Restricted Award Shares are allotted and issued to the relevant trustee. There is no restriction on when a selected participant is required to pay the grant consideration to the Company in order to have his/her Restricted Award Shares vested. The grant consideration (per Share) for each grant was determined primarily with reference to (i) for the grant made on 29 May 2020, the exercise price of the Pre-IPO Share Options; and (ii) for the grants made on 23 December 2021 and 1 November 2022, a balance being struck between the intended effect of the grant in terms of talent retention and incentivization and the expected profit and loss impact of such grant on the Group.

2024 RESTRICTED SHARE AWARD SCHEME

Vesting schedule	Subject to the rules of the 2024 Restricted Share Award Scheme, any Restricted Award Share granted to a selected participant shall vest in such selected participant on the latest of (i) the Vesting Date in respect of such Award Share; (ii) the date of the allotment and issue of such Restricted Award Share by the Company to the trustee or the date of purchase, migration or re-allocation of such Restricted Award Share, as the case may be; and (iii) the date of the receipt of the full amount of the grant consideration by the Company in respect of such Restricted Award Share. The Administration Committee shall have the absolute discretion in determining whether the vesting conditions of any Selected Participant has been fulfilled. The vesting period for Awards shall not be less than twelve (12) months, save and except that a shorter vesting period may be granted to employee participants as deemed appropriate at the sole discretion of the Administration Committee in any of the circumstances specified in the scheme rules.

If an offer by way of takeover, merger, scheme of arrangement, share repurchase or otherwise is made to all the holders of Shares (or all such holders other than the offeror, any person controlled by the offeror and any person acting in association or concert with the offeror) resulting in a change in control (as defined in the Takeovers Code) of the Company, and such offer becomes or is declared unconditional (i.e. all conditions to which such transaction is subject have been satisfied) prior to the vesting of Restricted Award Shares in the selected participant, then such Restricted Award Shares shall immediately so vest. For the avoidance of doubt, the vesting period in respect of awards granted to selected participants who are service provider participants shall not be less than twelve (12) months.

Acceptance of grant	After the Administration Committee has determined a selected participant and the terms and conditions of a grant, it shall notify the relevant trustee and the selected participant about these terms and conditions in writing. Upon receipt of such notification, the grant shall be deemed to be irrevocably accepted by the selected participant unless the selected participant notifies the Administration Committee in writing within five (5) business days that he/she declines to accept the grant.
Grant consideration	In determining the grant consideration of a grant under the 2024 Restricted Share Award Scheme, the Administration Committee shall take into consideration any matter which it considers relevant, including but not limited to (i) the prevailing market price of the Shares and the valuation of the Company at or around the time of the grant; (ii) the intended effect of the grant in terms of talent incentivization; and (iii) the profit and loss as well as cash flow impacts of the grant. The grant consideration is to be paid by a selected participant to the Company as a condition to the vesting of his/her Restricted Award Shares on or after the relevant vesting date, but not when the Restricted Award Shares are allotted and issued to the relevant trustee. There is no restriction on when a selected participant is required to pay the grant consideration to the Company in order to have his/her Restricted Award Shares vested.

The information contained in this supplemental announcement does not affect the other information contained in the 2024 Annual Report. Save as disclosed in this announcement, all the other information and contents in the 2024 Annual Report remain unchanged.

By order of the Board
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 31 December 2025

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.